JAK1 and rheumatoid arthritis: Filgotinib exhibits 30-fold greater selectivity for JAK1 over JAK2 [397], In phase II studies for RA (NCT01888874, NCT01888874), higher daily doses effectively controlled disease activity, demonstrating superiority over placebo both as monotherapy and in combination therapy.